SK-MM-2Homo sapiens (Human)Cancer cell line
Also known as: SKMM2, SKMM-2, SK-MM2
Quick Overview
Human multiple myeloma cell line with B-cell origin, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1699 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 54 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Multiple myeloma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Plasma Cell Myeloma |
| OncoTree Code | PCM |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000363_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Lys132Asn (c.396G>T) | Heterozygous | - | Unknown |
| Gene fusion | CCND1 | IGH-CCND1 | - | - | DOI=10.6342/NTU.2004.01000 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Pellat-Deceunynck C.
J. Hematol. Oncol. 11:137.1-137.13(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
Cytometry A 87:285-288(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Pellat-Deceunynck C.
Haematologica 96:574-582(2011).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Kuehl W.M.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
Kuehl W.M.
Blood 88:674-681(1996).
Establishment and characterization of two human myeloma cell lines secreting kappa light chains.
Eton O., Scheinberg D.A., Houghton A.N.
Leukemia 3:729-735(1989).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).